Article: Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleMolecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
AuthorsAhmed, N2
Corey, M2
Forstner, G2
Zielenski, J2
Tsui, LC2
Ellis, L
Tullis, E1
Durie, P2
Issue Date2003
PublisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
CitationGut, 2003, v. 52 n. 8, p. 1159-1164 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.52.8.1159
AbstractBackground and aims: We tested the hypothesis that the actual or predicted consequences of mutations in the cystic fibrosis transmembrane regulator gene correlate with the pancreatic phenotype and with measures of quantitative exocrine pancreatic function. Methods: We assessed 742 patients with cystic fibrosis for whom genotype and clinical data were available. At diagnosis, 610 were pancreatic insufficient, 110 were pancreatic sufficient, and 22 pancreatic sufficient patients progressed to pancreatic insufficiency after diagnosis. Results: We identified mutations on both alleles in 633 patients (85.3%), on one allele in 95 (12.8%), and on neither allele in 14 (1.9%). Seventy six different mutations were identified. The most common mutation was ΔF508 (71.3%) followed by G551D (2.9%), G542X (2.3%), 621+1G→T (1.2%), and W1282X (1.2%). Patients were categorized into five classes according to the predicted functional consequences of each mutation. Over 95% of patients with severe class I, II, and III mutations were pancreatic insufficient or progressed to pancreatic insufficiency. In contrast, patients with mild class IV and V mutations were consistently pancreatic sufficient. In all but four cases each genotype correlated exclusively with the pancreatic phenotype. Quantitative data of acinar and ductular secretion were available in 93 patients. Patients with mutations belonging to classes I, II, and III had greatly reduced acinar and ductular function compared with those with class IV or V mutations. Conclusion: The predicted or known functional consequences of specific mutant alleles correlate with the severity of pancreatic disease in cystic fibrosis.
ISSN0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
DOIhttp://dx.doi.org/10.1136/gut.52.8.1159
ISI Accession Number IDWOS:000184182300016
PubMed Central IDPMC1773762
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorAhmed, N
dc.contributor.authorCorey, M
dc.contributor.authorForstner, G
dc.contributor.authorZielenski, J
dc.contributor.authorTsui, LC
dc.contributor.authorEllis, L
dc.contributor.authorTullis, E
dc.contributor.authorDurie, P
dc.date.accessioned2007-01-29T08:52:24Z
dc.date.available2007-01-29T08:52:24Z
dc.date.issued2003
dc.description.abstractBackground and aims: We tested the hypothesis that the actual or predicted consequences of mutations in the cystic fibrosis transmembrane regulator gene correlate with the pancreatic phenotype and with measures of quantitative exocrine pancreatic function. Methods: We assessed 742 patients with cystic fibrosis for whom genotype and clinical data were available. At diagnosis, 610 were pancreatic insufficient, 110 were pancreatic sufficient, and 22 pancreatic sufficient patients progressed to pancreatic insufficiency after diagnosis. Results: We identified mutations on both alleles in 633 patients (85.3%), on one allele in 95 (12.8%), and on neither allele in 14 (1.9%). Seventy six different mutations were identified. The most common mutation was ΔF508 (71.3%) followed by G551D (2.9%), G542X (2.3%), 621+1G→T (1.2%), and W1282X (1.2%). Patients were categorized into five classes according to the predicted functional consequences of each mutation. Over 95% of patients with severe class I, II, and III mutations were pancreatic insufficient or progressed to pancreatic insufficiency. In contrast, patients with mild class IV and V mutations were consistently pancreatic sufficient. In all but four cases each genotype correlated exclusively with the pancreatic phenotype. Quantitative data of acinar and ductular secretion were available in 93 patients. Patients with mutations belonging to classes I, II, and III had greatly reduced acinar and ductular function compared with those with class IV or V mutations. Conclusion: The predicted or known functional consequences of specific mutant alleles correlate with the severity of pancreatic disease in cystic fibrosis.
dc.description.naturepublished_or_final_version
dc.format.extent103157 bytes
dc.format.extent30208 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypeapplication/msword
dc.identifier.citationGut, 2003, v. 52 n. 8, p. 1159-1164 [How to Cite?]
DOI: http://dx.doi.org/10.1136/gut.52.8.1159
dc.identifier.doihttp://dx.doi.org/10.1136/gut.52.8.1159
dc.identifier.epage1164
dc.identifier.isiWOS:000184182300016
dc.identifier.issn0017-5749
2011 Impact Factor: 10.111
2011 SCImago Journal Rankings: 0.883
dc.identifier.issue8
dc.identifier.openurl
dc.identifier.pmcidPMC1773762
dc.identifier.pmid12865275
dc.identifier.scopuseid_2-s2.0-0038298386
dc.identifier.spage1159
dc.identifier.urihttp://hdl.handle.net/10722/42535
dc.identifier.volume52
dc.languageeng
dc.publisherBMJ Publishing Group. The Journal's web site is located at http://gut.bmjjournals.com/
dc.publisher.placeUnited Kingdom
dc.relation.ispartofGut
dc.relation.referencesReferences in Scopus
dc.rightsGut. Copyright © B M J Publishing Group.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.subject.meshCystic fibrosis
dc.subject.meshCystic fibrosis transmembrane regulator
dc.subject.meshPancreatic insufficiency
dc.subject.meshPancreas
dc.subject.meshExocrine pancreatic insufficiency - genetics - physiopathology
dc.titleMolecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas
dc.typeArticle
Author Affiliations
  1. Saint Michael's Hospital, Toronto
  2. Hospital for Sick Children, Toronto